Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma

Activating KRAS mutations occur in about 30% of pulmonary adenocarcinoma (AC) cases and the discovery of specific inhibitors of G12C-mutated KRAS has considerably improved the prognosis for a subgroup of about 14% of non-small cell lung cancer (NSCLC) patients. However, even in patients with a KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuchan, Elakad, Omar, Yao, Sha, von Hammerstein-Equord, Alexander, Hinterthaner, Marc, Danner, Bernhard C., Ferrai, Carmelo, Ströbel, Philipp, Küffer, Stefan, Bohnenberger, Hanibal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324032/
https://www.ncbi.nlm.nih.gov/pubmed/35888776
http://dx.doi.org/10.3390/metabo12070652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324032/
https://www.ncbi.nlm.nih.gov/pubmed/35888776
http://dx.doi.org/10.3390/metabo12070652

Ejemplares similares